Brain and Central Nervous System Tumors Clinical Trial
Official title:
A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma
Verified date | May 2015 |
Source | Radiation Therapy Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as temozolomide. work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving veliparib together with temozolomide may kill more tumor cells.
PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of
giving veliparib together with temozolomide and to see how well it works in treating
patients with recurrent glioblastoma.
Status | Active, not recruiting |
Enrollment | 240 |
Est. completion date | |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed diagnosis of 1 of the following: - Any intracranial high-grade glioma (phase I*) - Glioblastoma or gliosarcoma (phase II*) - Patients whose original histology was low-grade glioma are eligible provided they were subsequently diagnosed with glioblastoma or gliosarcoma - Unequivocal radiographic evidence for tumor progression by MRI within 14 days prior to registration and with a stable or decreasing dose of steroids at least 5 days prior to scanning OR recent resection (registration within 30 days of resection) as long as all of the following conditions are met: - Patients must have recovered from the effects of surgery - Residual disease following resection of recurrent glioblastoma is not mandated for eligibility into the study; to best assess the extent of residual disease post-operatively, a post-operative MRI scan should be performed within 28 days prior to registration and within 96 hours post surgery (although 24 hours would be optimum) - Prior radiation is required for the phase I* arm - Patients must have completed a course of radiation therapy and at least 2 consecutive adjuvant cycles of temozolomide (phase II*) - A stable or decreasing dose of steroids at least 5 days prior to scanning is not mandated for patients who had a recent resection - No evidence of acute (i.e., new and active) intratumoral hemorrhage on MRI - Patients with MRI demonstrating old hemorrhage or subacute blood after a neurosurgical procedure (biopsy or resection) are eligible NOTE: *Phase I was closed and phase II was opened on 3/6/12. PATIENT CHARACTERISTICS: - Karnofsky performance status 70-100% - WBC = 3,000/mm^3 - ANC = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Hemoglobin = 10.0 g/dL (transfusion or other intervention allowed) - SGOT = 3.0 times upper limit of normal (ULN) - SGPT = 3.0 times ULN - Bilirubin = 1.25 times ULN - Creatinine < 1.7 mg/dL OR estimated GFR = 30 mL/min - Urine protein:creatinine ratio = 0.5 OR urine protein < 1,000 mg by 24-hour urine collection** - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for = 6 months after completion of study therapy - Able to undergo brain MRI scans with IV gadolinium - Able to swallow oral medications - Patients with a history of seizure, or new onset of seizures, should be clinically controlled with no seizures for at least 14 days prior to registration - No other prior invasive malignancy (except for nonmelanomatous skin cancer or carcinoma in situ of the cervix) unless the patient has been disease-free and off therapy for that disease for = 3 years - No severe, active comorbidity, including any of the following: - Transmural myocardial infarction or unstable angina within the past 6 months - Evidence of recent myocardial infarction or ischemia as indicated by S-T elevations of = 2 mm on EKG performed within the past 14 days - NYHA class II-IV congestive heart failure requiring hospitalization within the past 12 months - Stroke or transient ischemic attack within the past 6 months - Cerebral vascular accident within the past 6 months - Serious and inadequately controlled cardiac arrhythmia - Clinically significant peripheral vascular disease - Evidence of bleeding diathesis or coagulopathy - Serious non-healing would, ulcer, or bone fracture - Abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within the past 28 days - Significant traumatic injury within the past 28 days - Acute bacterial or fungal infection requiring IV antibiotics at the time of study registration - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within the past 14 days - AIDS based upon current CDC definition (HIV testing is not required) - No condition that would impair the ability to swallow pills (e.g., GI tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) - No disease that would obscure toxicity or dangerously alter drug metabolism - Not on dialysis - No history of chronic hepatitis B or C NOTE: **Required for patients who received prior bevacizumab and developed known clinically significant nephrotic syndrome during treatment and whose baseline values have not returned to normal. PRIOR CONCURRENT THERAPY: - See Disease Characteristics - Recovered from the toxic effects of prior therapy - Prior interstitial brachytherapy, Gliadel wafer, or stereotactic radiosurgery allowed provided there is confirmation of progressive disease by PET scan, thallium scan, MRI spectroscopy, perfusion MRI, or surgical documentation - No more than 3 prior treatment regimens (phase I*) - No more than 2 prior treatment regimens for recurrent glioblastoma/gliosarcoma (phase II*) - More than 28 days since prior major surgical procedure or open biopsy (with the exception of craniotomy) - At least 28 days since prior investigational agents or cytotoxic agents (42 days for nitrosoureas, 21 days for procarbazine, and 14 days for vincristine) - At least 14 days since prior non-cytotoxic agents (e.g., bevacizumab, interferon, tamoxifen, thalidomide, isotretinoin, or tyrosine kinase inhibitors) - No concurrent highly-active antiretroviral therapy - No concurrent herbal products of unknown constitution - No concurrent major surgical procedures NOTE: *Phase I was closed and phase II was opened on 3/6/12. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Chicago Cancer Research Center | Chicago | Illinois |
United States | Leeward Radiation Oncology | Ewa Beach | Hawaii |
United States | Cancer Research Center of Hawaii | Honolulu | Hawaii |
United States | Hawaii Medical Center - East | Honolulu | Hawaii |
United States | Queen's Cancer Institute at Queen's Medical Center | Honolulu | Hawaii |
United States | Rebecca and John Moores UCSD Cancer Center | La Jolla | California |
United States | Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire |
United States | Central Baptist Hospital | Lexington | Kentucky |
United States | Cedars-Sinai Medical Center | Los Angeles | California |
United States | Louisville Oncology at Norton Cancer Institute - Louisville | Louisville | Kentucky |
United States | Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School | New Brunswick | New Jersey |
United States | Regional Cancer Center at Singing River Hospital | Pascagoula | Mississippi |
United States | Legacy Good Samaritan Hospital & Comprehensive Cancer Center | Portland | Oregon |
United States | CCOP - Kansas City | Prairie Village | Kansas |
United States | Renown Institute for Cancer at Renown Regional Medical Center | Reno | Nevada |
United States | Highland Hospital of Rochester | Rochester | New York |
United States | James P. Wilmot Cancer Center at University of Rochester Medical Center | Rochester | New York |
Lead Sponsor | Collaborator |
---|---|
Radiation Therapy Oncology Group | National Cancer Institute (NCI), NRG Oncology |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose-limiting toxicity (Phase I) | The first 8 weeks. | Yes | |
Primary | 6-month progression-free survival rate (Phase II) | From randomization to 6 months. | No | |
Secondary | Treatment-related toxicity as measured by the NCI CTCAE version 4.0 | From start of treatment to end of follow-up. Analysis occurs at the same time as the primary outcome analysis. | Yes | |
Secondary | Objective response (partial and complete response) rate (Phase II) | From randomization to date of progression, death or last follow-up. Analysis occurs at the same time as the primary outcome analysis. | No | |
Secondary | Overall survival (Phase II) | From randomization to date of death or last follow-up. Analysis occurs at the same time as the primary outcome analysis. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 |